Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00416312 · ClinicalTrials.gov registry record
Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
A clinical trial, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- 9
- Enrollment target
NCT00416312: Completed study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT00416312 is a clinical trial that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00416312 has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab and yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. This may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: This clinical trial is studying the side effects, best dose, and how well iodine I 131 tositumomab or yttrium Y 90 ibritumomab tiuxetan works in treating patients with non-Hodgkin's lymphoma.
Primary Outcome
tumor absorbed dose (Gy)
Interventions
- DEVICE Patient-specific dosimetry
- DEVICE conventional dosimetry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-07 |
| Est. Completion | 2009-10 |
What the finished NCT00416312 record still lists
NCT00416312 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 9 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Patient-specific dosimetry is the first listed.
NCT00416312 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00416312 about?
NCT00416312 is a clinical study titled "Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma". RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab and yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. This may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: This clinica...
What is the current status of trial NCT00416312?
This trial is currently completed. The enrollment target is 9 participants. The study started on 2006-07. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00416312?
The interventions under investigation include: Patient-specific dosimetry (DEVICE), conventional dosimetry (DEVICE).
Who is sponsoring clinical trial NCT00416312?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia